HealthInvest Partners AB Increases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

HealthInvest Partners AB boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 9,202 shares of the company’s stock after acquiring an additional 1,578 shares during the period. Krystal Biotech comprises about 0.8% of HealthInvest Partners AB’s holdings, making the stock its 28th biggest holding. HealthInvest Partners AB’s holdings in Krystal Biotech were worth $1,675,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KRYS. Price T Rowe Associates Inc. MD raised its position in shares of Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Segall Bryant & Hamill LLC lifted its position in shares of Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after acquiring an additional 122,407 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Krystal Biotech by 1,972.0% in the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after acquiring an additional 117,510 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Krystal Biotech by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after purchasing an additional 103,928 shares in the last quarter. Finally, Capital World Investors purchased a new position in Krystal Biotech in the 1st quarter valued at $17,285,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Trading Up 1.4 %

KRYS stock traded up $2.51 during midday trading on Thursday, hitting $180.61. 1,593 shares of the company’s stock were exchanged, compared to its average volume of 326,196. Krystal Biotech, Inc. has a 1-year low of $99.00 and a 1-year high of $219.34. The stock has a market capitalization of $5.19 billion, a PE ratio of 100.62 and a beta of 0.82. The business has a 50-day simple moving average of $180.03 and a two-hundred day simple moving average of $181.99.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.67) EPS. As a group, research analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Chardan Capital raised their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus price target of $202.29.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).